Not available outside of the UK & Ireland.
Application
Anti-EFNA1 antibody produced in rabbit has been used in western blot analysis.
Biochem/physiol Actions
EphrinA1 (EFNA1) and its primary receptor, Eph receptor 2 (EphA2) are associated with various cancers, such as urinary bladder carcinoma, breast cancer gastric cancer, glioma and malignant mesothelioma. Expression pattern of EFNA1 can be used as a potential prognostic marker in colorectal cancer (CRC) patients and other human malignancies. Experimental studies state that, EphrinA1 (EFNA1) can be involved in both tumor promotion and inhibition, based on whether ephrin-A1 is bound to the receptor in soluble or membrane bound form, respectively. Activation of EphA2, induces indirect growth signal by overcoming ‘;contact inhibition’;.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
General description
EphrinA1 (EFNA1), also known as angiogenesis factor, is encoded by the gene mapped to human chromosome 1q21-22. The encoded protein belongs to subclass A of ephrin family. EFNA1 is localized to cell membrane via a glycosylphosphatidylinositol (GPI) moiety. EFNA1 ligand preferentially binds to the receptor tyrosine kinase, Eph receptor 2 (EphA2).
Immunogen
The antiserum was produced against synthesized peptide derived from human EFNA1.Immunogen Range: 66-115
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
This product has met the following criteria to qualify for the following awards: